XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Stockholders Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive (Loss)/Income
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   97,549,000      
Beginning balance at Dec. 31, 2020 $ 434,347 $ 10 $ 937,134 $ (261) $ (502,536)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense 7,224   7,224    
Issuance of common stock, net of issuance costs (in shares)   121,000      
Issuance of common stock, net of issuance costs 1,689   1,689    
Common stock issued upon exercise of stock options (in shares)   9,000      
Common stock issued upon exercise of stock options 51   51    
Common stock issued upon release of restricted stock units (in shares)   248,000      
Foreign currency translation adjustments (33)     (33)  
Unrealized loss on marketable securities, net (22)     (22)  
Net loss (28,436)       (28,436)
Ending balance (in shares) at Mar. 31, 2021   97,927,000      
Ending balance at Mar. 31, 2021 414,820 $ 10 946,098 (316) (530,972)
Beginning balance (in shares) at Dec. 31, 2021   98,381,000      
Beginning balance at Dec. 31, 2021 316,185 $ 10 964,965 (714) (648,076)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation expense $ 5,381   5,381    
Common stock issued upon exercise of stock options (in shares) 15,000 15,000      
Common stock issued upon exercise of stock options $ 3   3    
Common stock issued upon release of restricted stock units (in shares)   371,000      
Foreign currency translation adjustments 14     14  
Unrealized loss on marketable securities, net (723)     (723)  
Net loss (37,908)       (37,908)
Ending balance (in shares) at Mar. 31, 2022   98,767      
Ending balance at Mar. 31, 2022 $ 282,952 $ 10 $ 970,349 $ (1,423) $ (685,984)